LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Lipocine Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$1.53−0.03 (-1.92%)

Close on Oct 19, 2026

Market cap: $12.57M
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$1.98MFY2025, -9.9% a year since FY2012

Where these numbers come from

Parsed from the XBRL in Lipocine's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-17 reverse split on Aug 10, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LPCN.

Operating margin-800.8% · median -3235.5%

Net margin-755.1% · median -2440.8%

Company	Revenue	Growth
VTGN	$2.50M	–
OVID	$1.58M	-76.2%
LPCN	$1.57M	-62.7%
SPRB	–	–
ATXI	–	–
ORMP	–	–

Company

Next earnings (est.): Nov 5, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 14
Held by institutions: 36.2%
Auditor: Tanner LLP
SEC CIK: 1535955

Advertisement
300 × 250